Get the Stockscreener App
27.82
0.64%
-0.18
Pre-market:
27.76
-0.06
-0.22%
Lenz Therapeutics Inc stock is traded at $27.82, with a volume of 385.02K.
It is down -0.64% in the last 24 hours and down -0.82% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$28.00
Open:
$27.88
24h Volume:
385.02K
Relative Volume:
0.41
Market Cap:
$870.49M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-4.9703
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-9.44%
1M Performance:
-0.82%
6M Performance:
-4.69%
1Y Performance:
-22.36%
1-Day Range:
$27.65
$29.02
1-Week Range:
$27.07
$31.58
52-Week Range:
$16.54
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
27.82 | 876.12M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Will LENZ Therapeutics Inc. stock gain from strong economyJuly 2025 Highlights & Smart Swing Trading Alerts - Newser
Transcript : LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Lenz Therapeutics: A Close Look (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.1%Here's What Happened - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires New Stake in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea - marketscreener.com
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics and Lotus Pharmaceutical Submit New Drug Application for VIZZ in South Korea to Treat Presbyopia - Quiver Quantitative
LENZ Therapeutics (Nasdaq: LENZ) logs 2nd ex-US VIZZ filing, up to $125 million milestones - Stock Titan
Piper Sandler 37th Annual Healthcare Conference - LENZ Therapeutics
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics (Nasdaq: LENZ) to webcast three December investor conferences - Stock Titan
Olsson, Lenz therapeutics CCO, sells $261k in stock By Investing.com - Investing.com Australia
Building trade automation scripts for LENZ Therapeutics Inc.July 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Ranking LENZ Therapeutics Inc. among high performing stocks via toolsEarnings Recap Summary & Short-Term High Return Strategies - newser.com
How LENZ Therapeutics Inc. stock reacts to oil prices2025 Price Targets & High Return Stock Watch Alerts - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock - Investing.com
LENZ Therapeutics CCO Shawn Olsson Sells 10,000 Shares - TradingView
Officer Olsson Sells 10,000 ($261K) Of LENZ Therapeutics Inc [LENZ] - TradingView
Is LENZ Therapeutics Inc. stock a buy in volatile marketsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Signal strength of LENZ Therapeutics Inc. stock in tech scannersJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
How LENZ Therapeutics Inc. stock reacts to Fed rate cutsEarnings Risk Report & Technical Confirmation Alerts - newser.com
Is LENZ Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - newser.com
Combining price and volume data for LENZ Therapeutics Inc.Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Can LENZ Therapeutics Inc. stock maintain operating marginsRate Hike & Precise Swing Trade Entry Alerts - newser.com
Tools to assess LENZ Therapeutics Inc.’s risk profileWeekly Earnings Recap & Low Drawdown Trading Techniques - newser.com
Officer Olsson Files To Sell 40,000 Of LENZ Therapeutics Inc [LENZ] - TradingView
Chart overlay techniques for tracking LENZ Therapeutics Inc.Weekly Volume Report & Capital Protection Trading Alerts - newser.com
How interest rate cuts could boost LENZ Therapeutics Inc. stockWall Street Watch & Risk Adjusted Buy/Sell Alerts - newser.com
Will LENZ Therapeutics Inc. stock see PE expansionJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):